An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...
For the past 12 years, 69-year-old Bob Van Housen has been living with Parkinson’s disease. At first, in order to control his symptoms, Van Housen took a medication called levodopa. Without the ...
DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease · In a clinical trial, patients treated with DUOPA ...
Levodopa is most commonly administered orally, but this trial tested continuous, 24-hour levodopa delivery through a subcutaneous infusion pump. A total of 381 patients with Parkinson's disease in 16 ...
NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial
The ND0612L patch pump for moderate Parkinson's--Courtesy of NeuroDerm Investors were thrilled by the Phase IIa clinical trial results of NeuroDerm's ($NDRM ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
CLEVELAND, Ohio — Parkinson’s disease medication delivered through an infusion pump effectively reduces symptoms for longer periods of time, suggests an international trial co-led by a University of ...
April 18, 2012 — Continuous delivery of levodopa directly into the small intestine is showing promise as a treatment for patients with advanced Parkinson's disease (PD). A phase 3 study, to be ...
Too little levodopa — the gold-standard drug for the disease — will leave patients unable to move, while too much triggers ...
NORTH CHICAGO, Ill., Jan. 12, 2015 -- The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results